|
Market Closed -
London S.E.
11:29:55 2026-09-18 am EDT
|
5-day change | 1st Jan Change | ||
| 1,859.00 GBX | -2.16% |
|
+5.00% | +1.89% |
| 11:10am | European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading | MT |
| 04:05am | GSK plc : Deutsche Bank remains Neutral | ZD |
| Market Cap | 76.13B 102B 88.54B 83.79B 142B 9,735B 143B 998B 386B 4,948B 382B 373B 15,838B | P/E 2026 * |
14.6x | P/E 2027 * | 12.1x |
|---|---|---|---|---|---|
| Enterprise Value | 96.81B 129B 113B 107B 181B 12,380B 182B 1,269B 491B 6,291B 486B 475B 20,141B | EV / Sales 2026 * |
2.85x | EV / Sales 2027 * | 2.65x |
| Free-Float |
92.75% | Yield 2026 * |
3.66% | Yield 2027 * | 3.94% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | -2.29% | ||
| 1 week | +4.89% | ||
| Current month | +0.19% | ||
| 1 month | -1.64% | ||
| 3 months | -3.43% | ||
| 6 months | -5.86% | ||
| Current year | +1.78% |
| 1 week | 1,789.5 |  | 1,912 |
| 1 month | 1,770 | | 1,937 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,455 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/9/26 | Free | Compliance Officer | 7 | 0.0000% | ||
| 9/9/26 | Buy | Executive/Senior Manager | 7 | 0.0000% | ||
| 9/9/26 | Free | Executive/Senior Manager | 7 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.24% | +4.89% | +26.07% | +23.36% | 102B | |
| -0.56% | +2.91% | +50.49% | +100.98% | 1,027B | |
| -0.56% | +1.20% | +54.33% | +65.43% | 651B | |
| +0.05% | +2.78% | +19.04% | +71.66% | 467B | |
| -1.19% | +3.81% | +36.63% | +38.52% | 350B | |
| -0.62% | +3.02% | +19.36% | +25.43% | 268B | |
| -0.02% | +6.29% | +10.63% | +16.00% | 257B | |
| +0.74% | +1.36% | +38.67% | +45.35% | 205B | |
| +0.79% | +1.63% | -28.42% | -56.80% | 190B | |
| -0.36% | +4.75% | +32.50% | +99.09% | 187B | |
| Average | -0.44% | +2.94% | +25.93% | +42.90% | 370.38B | |
| Weighted average by Cap. | -0.44% | +2.74% | +34.60% | +60.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 45.31B 39.46B 37.35B 63.39B 4,339B 63.71B 445B 172B 2,205B 170B 166B 7,059B | 35.5B 47.4B 41.29B 39.08B 66.33B 4,540B 66.65B 465B 180B 2,307B 178B 174B 7,386B |
| Net income | 5.35B 7.14B 6.22B 5.89B 9.99B 684B 10.04B 70.11B 27.11B 348B 26.82B 26.23B 1,113B | 6.28B 8.39B 7.31B 6.92B 11.74B 804B 11.8B 82.38B 31.85B 408B 31.52B 30.82B 1,307B |
| Net Debt | 20.68B 27.61B 24.05B 22.76B 38.64B 2,644B 38.83B 271B 105B 1,344B 104B 101B 4,302B | 17.97B 23.99B 20.9B 19.78B 33.57B 2,298B 33.73B 236B 91.08B 1,168B 90.12B 88.12B 3,738B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | GBX 1,859.00 | -2.16% | 4,223,558 |
| 26-09-17 | GBX 1,900.00 | +1.85% | 9,894,223 |
| 26-09-16 | GBX 1,865.50 | +0.62% | 7,165,786 |
| 26-09-15 | GBX 1,854.00 | -0.03% | 4,902,189 |
| 26-09-14 | GBX 1,854.50 | +4.74% | 4,365,927 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
